Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 21:4:107-16.
doi: 10.2147/dddt.s11764.

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson  1 , Sisse R Ostrowski
Affiliations
Review

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson et al. Drug Des Devel Ther. .

Abstract

Background: Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

Objective: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital bleeding disorders.

Patients and methods: English-language databases were searched in September 2009 for reports of randomized controlled trials (RCTs) evaluating the ability of rFVIIa to restore hemostasis in patients with congenital bleeding disorders.

Results: Eight RCTs involving 256 hemophilic patients with antibodies against coagulation factors, also known as inhibitors, were identified. The evidence supporting the use of rFVIIa in these patients was weak with regard to dose, clinical setting, mode of administration, efficacy, and adverse events, given the limited sample size of each RCT and the heterogeneity of the studies.

Conclusion: The authors suggest that rFVIIa therapy in hemophilic patients with inhibitors should be based on the individual's ability to generate thrombin and form a clot, and not on the patient's weight alone. Therefore, assays for thrombin generation, such as whole-blood thromboelastography, have the potential to significantly improve the treatment of these patients.

Keywords: FEIBA; NovoSeven; RCT; coagulation factor IX; coagulation factor VIII; hemophilia; hemostasis; inhibitors; rFVIIa.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia. 2009;15(Suppl 1):S2–S7. - PubMed
    1. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8:280–287. - PubMed
    1. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964–97. Br J Haematol. 1999;104:909–914. - PubMed
    1. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290. - PubMed
    1. Goodeve A. The incidence of inhibitor development according to specific mutations – and treatment? Blood Coagul Fibrinolysis. 2003;14(Suppl 1):S17–S21. - PubMed

MeSH terms